Kalaris Therapeutics Inc

KLRSNASDAQHealthcare● Active

$4.20

+$0.03(+0.65%)

Market Cap$78500825

P/E Ratio—

52W High$11.88

52W Low$2.14

Avg Volume82K

Open$4.26

Beta0.14

Forecast Market Cap PE Ratio

Kalaris Therapeutics Inc (KLRS) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

klrs · stock forecast · 1 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 1 Wall Street analysts in the past 3 months

Buy

1 analysts

consensus

Rating Breakdown

Strong Buy

Buy

Hold

Sell

Strong Sell

Total: 1 · Buy rate: 100.0%

12-Month Price Target

High

$23.00

Consensus

$18.25

+337.6% upside

Low

$14.00

Median: $18 · Last Close: $4.17

The Kalaris Therapeutics Inc (KLRS) analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month KLRS price target is $18.25, representing +337.6% upside from the current price of $4.17.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $18 (337.6%)High $23Low $14

Consensus Target

$18.25

337.6% upside

High Target

$23

451.6%

Low Target

$14

235.7%

Current Price

$4.17

as of today

Based on analyst price targets, the KLRS stock price prediction for the next 12 months ranges from $14 to $23. The consensus KLRS price forecast of $18.25 implies 337.6% upside from the current price of $4.17.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

Date	Predicted Price	Change	Min	Max
2026-06-10	$4.00	↓ 3.97%	$3.93	$4.08

1-day model range: $3.93–$4.08. Peak: $4.08 (-3.97%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$2	—	$2	-50.0%
2028	$1	—	$2	-62.5%
2029	$1	—	$1	-67.2%
2030	$1	—	$1	-69.2%
2031	$1	—	$1	-70.2%

Confidence:Very Low

⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)38.0

MACDBEARISH

Moving Averages · KLRS · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$4.53SELL

MA 10$4.84SELL

MA 20$4.86SELL

MA 50$5.47SELL

MA 100$7.29SELL

MA 200$6.63SELL

Current $KLRS · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$4.51SELL

EMA 10$4.70SELL

EMA 20$4.91SELL

EMA 50$5.63SELL

EMA 100$6.32SELL

EMA 200$6.59SELL

Current $KLRS · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:

Date	Brokerage	Action	Rating
2026-05-13	Citizens	Maintains	Market Outperform→Market Outperform

Citizens2026-05-13

Maintains

Market Outperform→Market Outperform

Wall Street analysts have recently issued updated ratings on Kalaris Therapeutics Inc (KLRS) stock. Of the recent 1 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover KLRS.

Analyst Recommendation Trends

Buy ratings1 → 1

Hold ratings0 → 0

Sell ratings0 → 0

KLRS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

Revenue Next Year

$11M

EPS This Year

$-1.90

EPS Next Year

$-1.54

↓ 19.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast KLRS EPS of $-1.90 for the current fiscal year, based on estimates from 6 analysts. The KLRS revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The KLRS stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KLRS price target is $18.25 (+337.6% upside), with an analyst consensus of Buy.

The KLRS short-term stock prediction for tomorrow is $4.00 (-3.97%). The KLRS stock prediction for 2030 projects a range of $1–$1.

Kalaris Therapeutics Inc trades on NASDAQ under the ticker KLRS. The KLRS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Earnings Revenue PE Ratio Financials Market Cap Insider Trades Dividends Price History

Frequently asked questions

KLRS forecast · 8 questions

According to 1 Wall Street analysts, the average 12-month KLRS price target is $18.25, with a high forecast of $23.00 and a low of $14.00. The median price target is shown in the chart above when available. This implies +337.6% potential upside from the current price of $4.17.

KLRS price targetWhat is KLRS price targetKLRS analyst price targetKLRS 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.